Isomorphic Labs, a Google DeepMind spinoff, is set to begin testing its first AI-designed drugs by the end of this year, as announced by CEO Demis Hassabis at the World Economic Forum. The company highlights the transformative potential of AI in drug discovery, claiming it can expedite the process and reduce costs significantly. Currently, over 460 AI startups are focusing on drug development, with substantial investment in the field. Collaborations between these startups and big pharmaceutical companies like Eli Lilly and Novartis are seen as promising for future advancements in drug therapies.
By one estimate, there are over 460 AI startups currently working on drug discovery, of which over a quarter come from Europe.
That's the plan. We'll hopefully have some AI-designed drugs in clinical trials by the end of the year, " said Demis Hassabis.
Instead of spending years or even decades testing chemicals by hand, machine learning algorithms can sift through mountains of data to spot patterns.
I would expect in the next couple of years the first AI-designed drugs in the clinic."
#ai-drug-discovery #isomorphic-labs #pharmaceutical-innovation #clinical-trials #healthcare-technology
Collection
[
|
...
]